Breaking News

Tufts Study Boasts Growth in Big Pharma Biotech Products

November 14, 2013

Driven by new technologies, improved outcomes, and small molecule patent losses

The pharmaceutical industry, namely Big Pharma, has dramatically shifted its R&D focus from small molecule drugs to include a rapidly increasing number of biotechnology products, according to a new analysis from the Tufts Center for the Study of Drug Development.

Tufts CSDD found that biotech products accounted for 7% of revenue generated by the top 10 selling pharmaceutical-biotech products worldwide in 2001, and accounted for 71% in 2012. The transformation, according to Tufts CSDD director Kenneth I Kaitin, has been driven by new technologies enabling the development of products that improve disease outcomes and command high prices, as well as the patent expirations on many top-selling small molecule drugs.
 
Mr. Kaitin noted that novel technology platforms during the last three decades have spurred an extensive pipeline of products across a wide range of therapeutic areas. For example, in 1989 only 13 biotechnology products were commercially available and by 2012, that number had grown to 210.
 
The analysis reported also found that: the number of biotech products in clinical trials grew 155% in 11 years, from 355 in 2001 to 907 in 2012, with Big Pharma in 2012 engaged in 40% of all biotech products in development. Additionally, financing of biotech research increased from $10.5 billion in 2001 to $103 billion in 2012, and worldwide growth in product sales grew 353% between 2001 and 2012, from $36 billion to $163 billion.
 
The study was conducted by Ronald Evens, adjunct faculty and biotechnology consultant with Tufts CSDD.

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.